Enterprise Value

-41.05M

Cash

57.63M

Avg Qtr Burn

-5.712M

Short % of Float

0.73%

Insider Ownership

17.22%

Institutional Own.

9.34%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
LSTA12 (HONEDRA®) Details
Critical limb ischemia

Phase 3

Update

LSTA1 Details
Pancreatic cancer, Cancer

Phase 2b

Data readout

LSTA1 + Standard of care Details
Cancer, Solid tumor/s, Esophageal cancer, Head and neck cancer, Cholangiocarcinoma

Phase 2a

Data readout

LSTA1 + temozolomide Details
Cancer, Glioblastoma, Glioma

Phase 2a

Data readout

LSTA1 + nivolumab/FOLFIRINOX, Details
Cancer, Gastroesophageal adenocarcinomas

Phase 1/2

Data readout

Phase 1/2

Data readout

LSTA1 + FOLFIRINOX (neoadjuvant) + panitumumab Details
Pancreatic cancer, Cancer, Colorectal cancer

Phase 1/2

Data readout

Phase 1/2

Data readout

Failed

Discontinued

LSTA201 (CLBS201) Details
Chronic kidney disease

Failed

Discontinued

XOWNA (CLBS16) Details
Coronary Microvascular Dysfunction

Failed

Discontinued